Back to All Events

APIS goes to AMP 2024!


  • APIS Assay Technologies Ltd. Nelson Street Manchester, England, M13 United Kingdom (map)

Come and meet the APIS team to discover the:

  • The APIS Breast Cancer Subtyping Kit is a highly reproducible, RT-qPCR based IVD product (in certain territories) and RUO product for detecting standard (HER2, ER, PR, Ki67) and novel proliferative biomarkers. This assay can help direct clinicians to the right treatment more quickly with higher accuracy.

  • The APIS ESR1 qPCR Kit is an advanced qPCR assay for the sensitive and precise detection of mutations within the estrogen receptor gene. The Kit is a qualitative test, detecting eleven ESR1 mutations across exons 5 (E380Q), 7 (S463P) and 8 (P535H, L536R, L536Q, L536H, L536P, Y537C, Y537S, Y537N and D538G).

  • The new APIS PIK3CA qPCR Kit is a real-time qualitative PCR test for the detection of the five most prevalent activating mutations in the PIK3CA gene, using a sample of DNA extracted from either formalin-fixed, paraffin-embedded (FFPE) breast tumour tissue or blood plasma (cfDNA).

  • The APIS MET Alterations Kit is a RT-qPCR assay detecting both MET exon 14 skipping mutation and MET gene overexpression.

  • The new ESR1 dPCR Kit is a dPCR assay detecting 11 key mutations within the oestrogen receptor gene.

Use this link to contact us and schedule a meeting.

Don’t miss our poster sessions on:

  1. Highly Sensitive ESR1 Mutation Detection with the APIS Kit:  Performance and LoD Testing in Varied Wildtype Backgrounds

    Session: Solid Tumors                     

    Date: Friday, November 22nd

    Time: 9:15am – 10:15am Pacific

  2. Implementing Semi-quantitative Methods for Breast Cancer Biomarker Assessment Using the APIS Breast Cancer Subtyping Kit        

    Session: Solid Tumors                     

    Date: Saturday, November 23rd

    Time: 9:15am – 10:15am Pacific

  3. Advancing HER2 Stratification: Evaluating the APIS Breast Cancer Subtyping Kit Against IHC/ISH for Precise HER2 Quantification

    Session: Solid Tumors                     

    Date: Saturday, November 23rd

    Time: 9:15am – 10:15am Pacific

  4. Validating the APIS Breast Cancer Subtyping Kit: mRNA Expression of ER, PR, HER2 and Ki67 Compared to Immunohistochemistry in 374 Breast Cancer Core Needle Biopsies

    Session: Solid Tumors                     

    Date: Saturday, November 23rd

    Time: 9:15am – 10:15am Pacific

Previous
Previous
21 October

International Annual Meeting on Breakthroughs in breast cancer research and treatment

Next
Next
22 November

The Association of Breast Pathology (ABP) and the British Division of the International Academy of Pathology (BDIAP)